NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis $42.02 -0.03 (-0.07%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$41.59▼$42.6550-Day Range$31.49▼$48.8352-Week Range$19.80▼$49.06Volume191,073 shsAverage Volume778,556 shsMarket Capitalization$2.39 billionP/E RatioN/ADividend YieldN/APrice Target$50.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Agios Pharmaceuticals alerts: Email Address Agios Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside20.6% Upside$50.67 Price TargetShort InterestHealthy7.62% of Float Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews Sentiment0.49Based on 5 Articles This WeekInsider TradingSelling Shares$214,642 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.68) to ($5.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.71 out of 5 starsMedical Sector413th out of 896 stocksPharmaceutical Preparations Industry188th out of 424 stocks 2.3 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Agios Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.62% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 5.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgios Pharmaceuticals has received a 75.34% net impact score from Upright. Agios Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Agios Pharmaceuticals is -0.80. Previous Next 1.9 News and Social Media Coverage News SentimentAgios Pharmaceuticals has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Agios Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $214,642.00 in company stock.Percentage Held by InsidersOnly 4.93% of the stock of Agios Pharmaceuticals is held by insiders.Read more about Agios Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to decrease in the coming year, from ($2.68) to ($5.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Agios Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsMassive July 4th Discount InsideTo celebrate this Independence Day, we've arranged a special deal for you... We've partnered with Behind the Markets to make sure YOU get access to an exclusive 90% off sale not being offered to the public.Claim your exclusive offer here>>> About Agios Pharmaceuticals Stock (NASDAQ:AGIO)Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AGIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGIO Stock News HeadlinesJuly 4 at 4:38 AM | americanbankingnews.comStockNews.com Lowers Agios Pharmaceuticals (NASDAQ:AGIO) to SellJuly 4 at 1:16 AM | americanbankingnews.comShort Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Declines By 5.6%July 5, 2024 | Behind the Markets (Ad)Historic NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's next?July 2 at 1:48 AM | americanbankingnews.comReviewing Agios Pharmaceuticals (NASDAQ:AGIO) and Onconetix (NASDAQ:ONCO)June 27, 2024 | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.comJune 25, 2024 | americanbankingnews.comStockNews.com Downgrades Agios Pharmaceuticals (NASDAQ:AGIO) to SellJune 12, 2024 | seekingalpha.comAgios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising PipelineJune 3, 2024 | reuters.comAgios Pharmaceuticals' blood disorder drug succeeds in late-stage studyJuly 5, 2024 | Behind the Markets (Ad)Historic NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's next?June 3, 2024 | globenewswire.comAgios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-ThalassemiaMay 30, 2024 | globenewswire.comAgios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024May 28, 2024 | msn.comRoyalty Pharma Flat on Buying into AgiosMay 28, 2024 | finance.yahoo.comAgios cashes in on cancer drug again with $905M Royalty Pharma dealMay 28, 2024 | msn.comAgios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break OutMay 28, 2024 | finance.yahoo.comAgios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer DealMay 28, 2024 | finanznachrichten.deRoyalty Pharma plc: Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionMay 28, 2024 | markets.businessinsider.comAgios Pharma Stock Climbs On Royalty Pharma's Deal To Buy Royalty Stake In VorasidenibMay 28, 2024 | msn.comAgios in pact with Royalty Pharma for brain tumor candidateMay 28, 2024 | finance.yahoo.comAgios Announces $905 Million Purchase Agreement for Vorasidenib RoyaltyMay 14, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Inovio Pharmaceuticals (INO)May 14, 2024 | globenewswire.comAgios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid CongressMay 6, 2024 | finance.yahoo.comAgios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024May 5, 2024 | finance.yahoo.comEarnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 4, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comAgios Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2024 | globenewswire.comAgios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024May 3, 2024 | finance.yahoo.comQ1 2024 Agios Pharmaceuticals Inc Earnings CallSee More Headlines Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/04/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AGIO CUSIPN/A CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees383Year FoundedN/APrice Target and Rating Average Stock Price Target$50.67 High Stock Price Target$53.00 Low Stock Price Target$46.00 Potential Upside/Downside+20.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-352,090,000.00 Net Margins-1,199.26% Pretax Margin-1,199.26% Return on Equity-41.41% Return on Assets-36.36% Debt Debt-to-Equity RatioN/A Current Ratio12.84 Quick Ratio12.39 Sales & Book Value Annual Sales$29.40 million Price / Sales81.13 Cash FlowN/A Price / Cash FlowN/A Book Value$14.51 per share Price / Book2.90Miscellaneous Outstanding Shares56,773,000Free Float53,974,000Market Cap$2.39 billion OptionableOptionable Beta0.79 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Brian M. Goff M.B.A. (Age 55)CEO & Director Comp: $1.23MMs. Cecilia Jones (Age 49)Chief Financial Officer Comp: $403.36kMr. James William Burns (Age 46)Corporate Secretary & Chief Legal Officer Comp: $660.33kDr. Sarah Gheuens M.D. (Age 44)Ph.D., Chief Medical Officer and Head of Research & Development Comp: $769.2kDr. Lewis Clayton Cantley Ph.D. (Age 75)Co-Founder & Member of Scientific Advisory Board Comp: $50kDr. Tak Wah Mak D.Sc. (Age 78)FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Craig B. Thompson M.D. (Age 71)Co-Founder & Chairman of Scientific Advisory Board Dr. Shin-San Su Ph.D. (Age 68)Co-Founder & Member of Scientific Advisory Board Mr. T. J. Washburn Jr. (Age 43)Principal Accounting Officer Dr. Clive Patience Ph.D. (Age 60)Chief Technical Operations Officer More ExecutivesKey CompetitorsLegend BiotechNASDAQ:LEGNAscendis Pharma A/SNASDAQ:ASNDRoivant SciencesNASDAQ:ROIVCerevel TherapeuticsNASDAQ:CEREIntra-Cellular TherapiesNASDAQ:ITCIView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCBought 1,423,000 shares on 5/24/2024Ownership: 9.848%Tidal Investments LLCBought 32,336 shares on 5/17/2024Ownership: 0.057%Walleye Trading LLCSold 3,200 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 2,947 shares on 5/16/2024Ownership: 0.098%Caxton Associates LPBought 37,189 shares on 5/16/2024Ownership: 0.066%View All Insider TransactionsView All Institutional Transactions AGIO Stock Analysis - Frequently Asked Questions Should I buy or sell Agios Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AGIO shares. View AGIO analyst ratings or view top-rated stocks. What is Agios Pharmaceuticals' stock price target for 2024? 4 brokers have issued 12 month target prices for Agios Pharmaceuticals' stock. Their AGIO share price targets range from $46.00 to $53.00. On average, they anticipate the company's share price to reach $50.67 in the next twelve months. This suggests a possible upside of 20.6% from the stock's current price. View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts. How have AGIO shares performed in 2024? Agios Pharmaceuticals' stock was trading at $22.27 at the start of the year. Since then, AGIO shares have increased by 88.7% and is now trading at $42.02. View the best growth stocks for 2024 here. Are investors shorting Agios Pharmaceuticals? Agios Pharmaceuticals saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 4,220,000 shares, a drop of 5.6% from the May 31st total of 4,470,000 shares. Based on an average daily trading volume, of 795,400 shares, the days-to-cover ratio is presently 5.3 days. Currently, 7.6% of the company's shares are short sold. View Agios Pharmaceuticals' Short Interest. When is Agios Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our AGIO earnings forecast. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.65) by $0.20. The biopharmaceutical company had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative trailing twelve-month return on equity of 41.41% and a negative net margin of 1,199.26%. Agios Pharmaceuticals's quarterly revenue was up 46.0% compared to the same quarter last year. During the same period last year, the firm posted ($1.47) EPS. What ETFs hold Agios Pharmaceuticals' stock? ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include WisdomTree BioRevolution Fund (WDNA), Tema Oncology ETF (CANC), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Harbor Corporate Culture Small Cap ETF (HAPS), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Small Cap Growth AlphaDEX Fund (FYC). What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO? 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX). How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AGIO) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredGet in before Reddit doesRobinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.